HK1087399A1 - Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters - Google Patents

Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters

Info

Publication number
HK1087399A1
HK1087399A1 HK06107724A HK06107724A HK1087399A1 HK 1087399 A1 HK1087399 A1 HK 1087399A1 HK 06107724 A HK06107724 A HK 06107724A HK 06107724 A HK06107724 A HK 06107724A HK 1087399 A1 HK1087399 A1 HK 1087399A1
Authority
HK
Hong Kong
Prior art keywords
purebases
giphenylpropylamine
monoesters
highly
pharmaceutical formulations
Prior art date
Application number
HK06107724A
Other languages
English (en)
Inventor
Breitenbach Armin
Meese Claus
Wolff Hans-Michael
Drews Roland
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of HK1087399A1 publication Critical patent/HK1087399A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
HK06107724A 2003-04-08 2006-07-10 Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters HK1087399A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10315917A DE10315917A1 (de) 2003-04-08 2003-04-08 Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
PCT/EP2004/003567 WO2004089872A1 (de) 2003-04-08 2004-04-03 Hochreine basen von 3,3-diphenylpropylaminmonoestern

Publications (1)

Publication Number Publication Date
HK1087399A1 true HK1087399A1 (en) 2006-10-13

Family

ID=33154113

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107724A HK1087399A1 (en) 2003-04-08 2006-07-10 Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters

Country Status (17)

Country Link
US (2) US20060014832A1 (xx)
EP (1) EP1613584B1 (xx)
JP (2) JP4651035B2 (xx)
KR (1) KR100912451B1 (xx)
CN (1) CN100475775C (xx)
AU (1) AU2004228163B2 (xx)
BR (1) BRPI0406221A (xx)
CA (1) CA2505848A1 (xx)
DE (2) DE10315917A1 (xx)
ES (1) ES2297409T3 (xx)
HK (1) HK1087399A1 (xx)
MX (1) MXPA05003562A (xx)
NO (1) NO20055078L (xx)
RU (1) RU2394019C2 (xx)
UA (1) UA81803C2 (xx)
WO (1) WO2004089872A1 (xx)
ZA (1) ZA200502679B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1902708A1 (de) * 2006-09-25 2008-03-26 Losan Pharma GmbH Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
JP5254799B2 (ja) * 2006-09-26 2013-08-07 株式会社カネカ 遊離アミンの製造方法
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8374102B2 (en) * 2007-10-02 2013-02-12 Tellabs Communications Canada, Ltd. Intelligent collection and management of flow statistics
AU2009247782C1 (en) * 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
WO2011029005A1 (en) 2009-09-03 2011-03-10 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline forms of fesoterodine fumarate and fesoterodine base
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
CN109113555B (zh) 2013-03-15 2020-06-09 亨特道格拉斯公司 用于辊支撑的建筑覆盖件的位置锁定
JP6280219B2 (ja) 2013-11-29 2018-02-14 キム， ノ ウルＫＩＭ， Ｎｏ Ｅｕｌ プラスチック温水ボイラ

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE766207C (de) 1940-07-08 1952-12-22 Ig Farbenindustrie Ag Verfahren zur Herstellung von basischen Verbindungen der Diarylmethanreihe
DE925468C (de) * 1941-08-13 1955-03-21 Hoechst Ag Verfahren zur Herstellung von ª†, ª†-Diaryl-propyl-aminen
GB624117A (en) * 1946-12-07 1949-05-27 Wellcome Found Improvements in and relating to the preparation of substituted allylamines and propylamines
GB627139A (en) * 1947-05-28 1949-07-29 Wellcome Found Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines
NL70759C (xx) 1947-10-28
US2567245A (en) * 1948-05-10 1951-09-11 Schering Corp Aryl-(2-pyridyl)-amino alkanes and their production
US2556636A (en) * 1948-06-23 1951-06-12 Schering Corp gamma-substituted propylamine type antihistamines
DE830193C (de) 1948-11-09 1952-02-04 Farbwerke Hoechst Vormals Meis Verfahren zur Herstellung von basischen Verbindungen
CH285389A (de) 1948-11-09 1952-08-31 Michael Dr Erlenbach Verfahren zur Herstellung einer basischen Verbindung.
GB685696A (en) 1948-11-23 1953-01-07 Schering Corp Process for the manufacture of anti-histaminic compounds
NL74271C (xx) 1949-09-05
US2676964A (en) * 1950-06-07 1954-04-27 Schering Corp 3-pyridyl propylamine antihistamine substances
US3261841A (en) * 1961-05-03 1966-07-19 Sterling Drug Inc N-substituted 1,5-iminocycloalkanes and -alkenes
DK111894A (xx) * 1962-11-15
GB1025041A (en) * 1964-02-21 1966-04-06 Hoechst Ag Process for the manufacture of diphenylalkylamines
GB1169944A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
GB1169945A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
US4675009A (en) * 1977-11-07 1987-06-23 Lec Tec Corporation Drug dispensing device for transdermal delivery of medicaments
HU200591B (en) * 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
AU666735B2 (en) * 1992-05-13 1996-02-22 Alza Corporation Transdermal administration of oxybutynin
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
CA2259012C (en) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
CA2274832A1 (en) 1996-12-12 1998-06-18 Dds Drug Delivery Service Gesellschaft Zur Forderung Der Forschung In Ph Armazeutischer Technologie Und Biopharmazie Mbh Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0872233A1 (en) 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
WO1998056359A2 (de) * 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
DK1039882T3 (da) * 1998-08-27 2011-01-24 Pfizer Health Ab Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
CN100353935C (zh) * 1999-11-11 2007-12-12 法马西雅公司 含托特罗定的药物制剂及其应用
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
US6566537B2 (en) * 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
PL370539A1 (en) * 2001-09-04 2005-05-30 Pfizer Inc. Assay
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
KR20040039436A (ko) * 2001-09-27 2004-05-10 파마시아 에이비 약학 조성물
WO2003035599A1 (en) * 2001-10-26 2003-05-01 Pharmacia & Upjohn Company Quarternary ammonium compounds and their use as antimuscarinic agents
EP1441706A2 (en) * 2001-11-05 2004-08-04 Pharmacia & Upjohn Company Antimuscarinic aerosol
CA2467555A1 (en) * 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
AU2002360717A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Controlled release dosage form having improved drug release properties
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
US20060257482A1 (en) * 2002-06-07 2006-11-16 Patrik Kumar Modified release, multiple unit drug delivery systems
ITMI20021329A1 (it) * 2002-06-14 2003-12-15 Recordati Chem Pharm Nuove ossialchilammine sostituite
WO2004019892A2 (en) * 2002-08-30 2004-03-11 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
TW200408955A (en) * 2002-09-30 2004-06-01 Advent Networks Inc Implementing request/reply programming semantics using publish/subscribe middleware
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
BRPI0409653A (pt) * 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica

Also Published As

Publication number Publication date
CA2505848A1 (en) 2004-10-21
RU2394019C2 (ru) 2010-07-10
EP1613584A1 (de) 2006-01-11
RU2005134170A (ru) 2006-07-27
CN1802345A (zh) 2006-07-12
NO20055078L (no) 2005-10-31
DE502004005560D1 (de) 2008-01-03
ES2297409T3 (es) 2008-05-01
MXPA05003562A (es) 2005-06-03
AU2004228163A1 (en) 2004-10-21
EP1613584B1 (de) 2007-11-21
JP2010215643A (ja) 2010-09-30
US20060014832A1 (en) 2006-01-19
US20090012159A1 (en) 2009-01-08
US7989654B2 (en) 2011-08-02
DE10315917A1 (de) 2004-11-18
JP4651035B2 (ja) 2011-03-16
UA81803C2 (xx) 2008-02-11
ZA200502679B (en) 2006-04-26
CN100475775C (zh) 2009-04-08
BRPI0406221A (pt) 2005-08-09
KR100912451B1 (ko) 2009-08-14
AU2004228163B2 (en) 2007-06-07
WO2004089872A1 (de) 2004-10-21
KR20060006012A (ko) 2006-01-18
JP2006522758A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
HK1087399A1 (en) Pharmaceutical formulations comprising highly purebases of 3, 3-giphenylpropylamine monoesters
GB0319041D0 (en) Pharmaceutical Formulations
IL164519A0 (en) Pharmaceutical formulations
IL172824A0 (en) Pharmaceutical formulations
GB0302671D0 (en) Pharmaceutical formulations
IL156716A0 (en) Pharmaceutical formulation
EP1435894A4 (en) CYTOPROTECTIVE COMPOUNDS, METHODS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS
GB0118689D0 (en) Pharmaceutical formulation
PL366432A1 (en) Pharmaceutical formulation
GB2392093B (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
GB0302672D0 (en) Pharmaceutical formulations
GB0202900D0 (en) Novel formulations of drugs
GB2380129B (en) Pharmaceutical formulations
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en) Pharmaceutical formulations
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
GB0316341D0 (en) Pharmaceutical formulations
EP1448203A4 (en) PHARMACEUTICAL PREPARATIONS COMPRISING SUBSTITUTED XANTHIN COMPOUNDS
AU2003295846A8 (en) Pharmaceutical formulations of celcoxib
GB0124455D0 (en) Pharmaceutical formulations
GB0104749D0 (en) Pharmaceutical formulation
ZA200204905B (en) Improved pharmaceutical dental formulations.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200409